Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection

Journal of Immunotherapy

Volumn 24, Issue 2, 2001, Pages 172-183

  Karanikas, Vaios ^a   Thynne, Grenville ^b   Mitchell, Paul ^b   Ong, Chin Swee ^a   Gunawardana, Dishan ^a   Blum, Robert ^a   Pearson, Julian ^a   Lodding, Jodie ^a   Pietersz, Geoff ^a   Broadbent, Russell ^b   Tait, Brian ^b   McKenzie, Ian F C ^b  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Cancer; Clinical Trials; Immunotherapy; Vaccine

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; MUC1 MANNAN FUSION PROTEIN; MUCIN; MUCIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIBODY TITER; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DOSE CALCULATION; DRUG ADMINISTRATION ROUTE; DRUG CROSS REACTIVITY; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; BREAST NEOPLASMS; CA-15-3 ANTIGEN; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ACTIVE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; LYMPHOCYTE ACTIVATION; MANNANS; MIDDLE AGED; NEOPLASMS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 0035126975     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200103000-00012     Document Type: Article

References (21)

1. Taylor-Papadimitriou J, Gendler SJ. Molecular aspects of mucins. Cancer Rev 1988; 11:11-24.
2. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol 1995; 57:607-34.
3. Apostolopoulos V, Pietersz GA, Loveland BE, et al. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci USA 1995; 92:10128-32.
4. Karanikas V, Hwang L, Pearson J, et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mMannan-MUC1 fusion protein. J Clin Invest 1997; 100:2783-92.
5. Apostolopoulos V, Popovski V, McKenzie IFC. Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1-mannan fusion protein (M-FP). J Immunother 1998; 21:109-13.
6. Berd D, Maguire H, Mastrangelo MJ. Induction of cell mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986; 46:2572-7.
7. Kleinknecht S, Bichler KH, Strohmaier WL. Immune modulating effects of low doses of cyclophosphamide and keyhole limpet hemocyanin on peripheral blood immune parameters in patients with metastatic renal cell carcinoma. Urol Int 1992; 48:1-8.
8. Miles DW, Towlson KE, Graham R, et al. A randomised phase II study of sialyl-Tn and Detox-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 1996; 74:1292-6.
9. Pietersz GA, Li W, Popovski V, et al. Parameters for using mannan-MUC1 fusion protein to induce cellular immunity. Cancer Immunol Immunother 1998; 45:321-6.
10. Todryk SM, Kelly CG, Lehner T. Effect of route of immunization and adjuvant on T and B cell epitope recognition within a streptococcal antigen. Vaccine 1998; 16:174-80.
11. Apostolopoulos V, Pietersz GA, McKenzie IFC. Cell-mediated immune response to MUC1 fusion protein coupled to mannan. Vaccine 1996; 14:930-8.
12. Karanikas V, Lodding J, Maino V, et al. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin Cancer Res 2000; 6:829-837.
13. Xing PX, Apostolopoulos V, Michaels M, et al. Phase I study of synthetic MUCI peptides in cancer. Int J Oncol 1995; 6:1283-9.
14. Goydos JS, Elder E, Whiteside TL, et al. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996; 63:298-304.
15. Apostolopoulos V, Chelvanayagam G, Xing PX, et al. Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules. J Immunol 1998; 2:767-75.
16. Apostolopoulos V, Osinski C, McKenzie IFC. MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat Med 1998; 4:315-20.
17. Reddish M, Maclean GD, Koganty RR, et al. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 1998; 6:817-23.
18. Romero P, Dunbar RP, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998; 188:1641-50.
19. Maclean GD, Reddish MA, Koganty RR, et al. Antibodies against mucin-associated Sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunotherapy 1996; 19:59-68.
20. Agrawal B, Gendler SJ, Longenecker BM. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol Med Today 1998; 4:397-403.
21. Agrawal B, Krantz MJ, Parker J, et al. Expression of MUC1 mucin on activated human T cells: Implications for a role of MUC1 in normal immune regulation. Cancer Res 1998; 58:4079-81.